منابع مشابه
Dopamine Agonists
Dopamine agonists (DA) have been used to treat symptoms of Parkinson’s disease (PD) since the late 1970s (1). These agents were initially introduced to supplement the beneficial effect and possibly reduce the incidence of longterm complications of levodopa. In the last 30 years, methodical investigations of DA have demonstrated therapeutic benefit in all stages of PD both in combination with le...
متن کاملPotency ratio between opioid agonists and partial agonists.
POTENCY RATIO BETWEEN OPIOID AGONISTS AND PARTIAL AGONISTS Sir,—The paper by Klepper and colleagues (1986) again seems to indicate the belief of this group of workers in a fixed potency ratio between opioid agonists and partial agonists, although such a concept is theoretically unlikely (Kay, 1985). Support for a variable potency ratio is apparent in their paper, however, in that nalbuphine in ...
متن کاملNew MT2 Melatonin Receptor-Selective Ligands: Agonists and Partial Agonists
The search for melatonin receptor agonists and antagonists specific towards one of the receptor subtypes will extend our understanding of the role of this system in relaying circadian information to the body. A series of compounds derived from a hit compound discovered in a screening process led to powerful agonists specific for one of the isoform of the melatonin receptor namely, MT₂. The comp...
متن کاملNeuroprotection by dopamine agonists.
Research on Parkinson's disease has led to new hypotheses concerning the mechanisms of neurodegeneration and to the development of neuroprotective agents. Recent findings of impaired mitochondrial function, altered iron metabolism and increased lipid peroxidation in the substantia nigra of parkinsonian patients emphasize the significance of oxidative stress and free radical formation in the pat...
متن کاملPartial agonists in schizophrenia
The editorial by Bolonna & Kerwin (2005) is both timely and important. The authors succinctly present the case for the use of partial agonists of dopamine receptors, concluding that ‘the reviewed evidence suggests a promising future for dopamine receptor partial agonists’. While this is arguably true on the basis of the evidence presented, theoretical and empirical concerns regarding the use of...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Reactions Weekly
سال: 2021
ISSN: ['1179-2051', '0114-9954']
DOI: https://doi.org/10.1007/s40278-021-95737-6